Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relation to: TLX591-CDx (Illuccix® in approved jurisdictions, 68Ga-PSMA-11): ...

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...
Le Lézard

Pantheon Resources PLC Announces Shareholder Letter and Corporate Update on Dubhe-1

LONDON, UK / ACCESS Newswire / December 22, 2025 / Pantheon Resources plc (AIM:PANR) ("Pantheon" or the "Company"), the oil and gas company developing the Kodiak and Ahpun oil fields near pipeline and ...
Cantech Letter

Homeland Confirms Southward Continuity of Anomalous Radioactivity at the Coyote Basin Uranium Project

Homeland Uranium Corp. (TSXV: HLU) (OTCQB: HLUCF) (FSE: D3U) (“Homeland” or the “Company”) is pleased to provide a second update ...

Homeland Uranium Corp.: Homeland Confirms Southward Continuity of Anomalous Radioactivity at the Coyote Basin Uranium Project

Homeland Uranium Corp. (TSXV: HLU) (OTCQB: HLUCF) (FSE: D3U) ("Homeland" or the "Company") is pleased to provide a second update ...